PREPARATION FOR IMPROVING ACTIVITY AND/OR THERMAL STABILITY OF SUPEROXIDE DISMUTASE, AND APPLICATION THEREOF

Abstract

The present disclosure provides a preparation for improving activity and/or thermal stability of superoxide dismutase, and an application thereof. The preparation includes at least one of vitamin C, vitamin p, catechin, quercetin, myricetin, kaempherol, ellagic acid, or ferulic acid.

Claims

1. A preparation for improving activity and/or thermal stability of superoxide dismutase, comprising at least one of vitamin C, vitamin p, catechin, quercetin, myricetin, kaempherol, ellagic acid, or ferulic acid.

2. Use of the preparation according to claim 1 in improving activity of superoxide dismutase.

3. Use of the preparation according to claim 1 in improving thermal stability of superoxide dismutase.

4. A composition, comprising: superoxide dismutase; and the preparation according to claim 1.

5. The composition according to claim 4, wherein a concentration ratio of each of the vitamin C, the vitamin p, the catechin, the quercetin, the myricetin, the kaempherol, the ellagic acid, and the ferulic acid to the superoxide dismutase is independently 1:(1 to 10).

6. A method for improving activity of superoxide dismutase, comprising: contacting the superoxide dismutase with the preparation according to claim 1.

7. The method according to claim 6, wherein a concentration ratio of each of the vitamin C, the vitamin p, the catechin, the quercetin, the myricetin, the kaempherol, the ellagic acid, and the ferulic acid to the superoxide dismutase is independently 1:(1 to 10).

8. A method for improving thermal stability of superoxide dismutase, comprising: contacting the superoxide dismutase with the preparation according to claim 1.

9. The method according to claim 8, wherein a concentration ratio of each of the vitamin C, the vitamin p, the catechin, the quercetin, the myricetin, the kaempherol, the ellagic acid, and the ferulic acid to the superoxide dismutase is independently 1:(1 to 10).

10. A food, medicine, health care product, or kit, comprising the composition according to claim 4.

11. A food, medicine, health care product, or kit, comprising the composition according to claim 5.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0017] The above and/or additional aspects and advantages of the present disclosure will become more apparent and more understandable from the following description of embodiments taken in conjunction with the accompanying drawings, in which:

[0018] FIG. 1 is a schematic diagram showing an analysis of influences of different small-molecule substances on thermal stability of SOD at 80° C. according to an embodiment of the present disclosure.

DESCRIPTION OF EMBODIMENTS

[0019] Solutions of the present disclosure will be explained below in conjunction with the embodiments. It can be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present disclosure, and should not be construed as a limitation on the scope of the present disclosure. Where a specific technique or condition is not indicated in the embodiments, an implementation can be performed in accordance with the technique or condition described in a literature in the field or a product specification. A reagent or instrument used herein without specifying a manufacturer is a conventional product that can be obtained from the market.

Embodiment 1

[0020] In this embodiment, influences of different small-molecule substances on superoxide dismutase were studied.

[0021] 1. Reagents

[0022] Vc solution: 1.8 mg of vitamin C was weighed and dissolved in 10 mL of water to obtain a stock solution of C.sub.vc=1×10.sup.−3 mol/L.

[0023] Vp solution: 6.1 mg of vitamin P was weighed and dissolved in 10 mL of ethanol to obtain a stock solution of C.sub.vp=1×10.sup.−3 mol/L.

[0024] Catechin solution: 2.9 mg of catechin was weighed and dissolved in 10 mL of ethanol to obtain a stock solution of C.sub.catechin=1×10.sup.−3 mol/L.

[0025] Quercetin solution: 3.0 mg of quercetin was weighed and dissolved in 10 mL of ethanol to obtain a stock solution of C.sub.quercetin=1×10.sup.−3 mol/L.

[0026] Myricetin solution: 3.2 mg of myricetin was weighed and dissolved in 10 mL of ethanol to obtain a stock solution of C.sub.myricetin=1×10.sup.−3 mol/L.

[0027] Kaempherol solution: 2.9 mg of kaempherol was weighed and dissolved in 10 mL of ethanol to obtain a stock solution of C.sub.kaempherol=1×10.sup.−3 mol/L.

[0028] Ellagic acid solution: 3.0 mg of ellagic acid was weighed and dissolved in 10 mL of ethanol to obtain a stock solution of C.sub.ellagic acid=1×10.sup.−3 mol/L.

[0029] Ferulic acid solution: 1.9 mg of ferulic acid was weighed and dissolved in 10 mL of ethanol to obtain a stock solution of C.sub.ferulic acid=1×10.sup.−3 mol/L.

[0030] VB1 solution: 3.4 mg of vitamin B1 was weighed and dissolved in 10 mL of water to obtain a stock solution of C.sub.vb1=1×10.sup.−3 mol/L.

[0031] SOD solution: Mr(SOD)=37.8 kDa, 37.8 mg of SOD was weighed and dissolved in 10 mL of phosphate buffer to obtain a stock solution of C.sub.SOD=1×10.sup.−4 mol/L.

[0032] 2. Steps

[0033] Experimental group 1: 100 μL of the SOD solution was taken out and added to each of five 10 mL centrifuge tubes, and then 100 μL of the solution of each of the vitamin C, the vitamin p, the catechin, the quercetin, the myricetin, the kaempherol, the ellagic acid, and the ferulic acid was added to each of the five centrifuge tubes. Another 100 μL of the SOD solution was taken out as blank control. The centrifuge tubes and the blank control were placed in a water bath at 80° C., incubated for 4 hours, and detected for enzyme activity every 20 minutes.

[0034] Experimental group 2: 100 μL of the SOD solution was taken out and added to each of five 10 mL centrifuge tubes, and then 70 μL of the solution of each of the vitamin C, the vitamin p, the catechin, the quercetin, the myricetin, the kaempherol, the ellagic acid, and the ferulic acid was added to each of the five centrifuge tubes. Another 100 μL of the SOD solution was taken out as blank control. The centrifuge tubes and the blank control were placed in a water bath at 80° C., incubated for 4 hours, and detected for enzyme activity every 20 minutes.

[0035] Experimental group 3: 100 μL of the SOD solution was taken out and added to each of five 10 mL centrifuge tubes, and then 50 μL of the solution of each of the vitamin C, the vitamin p, the catechin, the quercetin, the myricetin, the kaempherol, the ellagic acid, and the ferulic acid was added to each of the five centrifuge tubes. Another 100 μL of the SOD solution was taken out as blank control. The five 10 mL centrifuge tubes and the blank control were placed in a water bath at 80° C., incubated for 4 hours, and detected for enzyme activity every 20 minutes.

[0036] Results of the experimental groups 1 to 3 are similar, and the following analysis is made by only taking experimental data of the experimental group 1 as an example. A result is illustrated in FIG. 1. It can be seen that an addition of each of the vitamin C, the vitamin p, the catechin, the quercetin, the myricetin, the kaempherol, the ellagic acid, and the ferulic acid can improve the activity of the SOD, and significantly improve the thermal stability of the SOD, while Vb1 fails to improve the activity and thermal stability of SOD enzymes (a curve of Vb1, which is not illustrated in the FIGURE, almost coincides with a curve of the SOD in a control group).

[0037] Reference throughout this specification to “an embodiment,” “some embodiments,” “an example,” “a specific example,” or “some examples,” means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present disclosure. The appearances of the above phrases in various places throughout this specification are not necessarily referring to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. In addition, different embodiments or examples and features of different embodiments or examples described in the specification may be combined by those skilled in the art without mutual contradiction.

[0038] Although embodiments of the present disclosure have been shown and described above, it should be understood that above embodiments are merely exemplary, and cannot be construed as limiting the present disclosure. For those skilled in the art, changes, modifications, substitutions, and variations can be made to the embodiments without departing from the scope of the present disclosure.